Baseline participant clinical and demographic characteristics

Number of patients43
Current/former smokers23/20
Number of exacerbations38
Number of exacerbations in the past 12 months)
Age (years)64.5 (59.4–70.8)
Smoking history (pack-years)38.0 (25.5–53.0)
Body mass index (kg·m−2)25.9 (23.6–28.0)
Daily dose of ICS (µg)#800 (500–1000)
Pre-study treatment regimen
Post-bronchodilator lung function
 FEV1 (% pred)64.1 (52.0–76.1)
 FEV1/FVC0.52 (0.44–0.56)
 TLC (% pred)112.1 (105.9–122.0)
 RV (% pred)135.5 (124.9–158.5)
 RV/TLC (% pred)114.9 (103.4–127.4)
Baseline inflammatory characteristics
 Sputum cells
  Eosinophils (%)1.8 (0.7–4.0)
  Neutrophils (%)72.8 (67.0–80.3)
  Macrophages (%)18.0 (13.4–25.3)
  Lymphocytes (%)0.7 (0.1–1.2)
  Bronchial epithelial cells (%)2.0 (0.65–3.55)
 Sputum supernatant proteins
  ECP (µg·L−1)194.0 (58.6–718.0)
  LTB4 (ng·mL−1)0.49 (0.28–1.21)

Data are presented as n or median (interquartile range). ICS: inhaled corticosteroid; LABA: long-acting β-agonist; LAMA: long-acting muscarinic antagonist; FEV1: forced expiratory volume in 1 s; FVC: forced vital capacity; TLC: total lung capacity; RV: residual volume; ECP: eosinophilic cationic protein; LTB4: leukotriene-B4. #: daily dose of ICS calculated for indexed budesonide equivalent; : additional short-acting β-agonist and/or short-acting muscarinic antagonist as needed.